NCT07101445View on ClinicalTrials.gov

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Acetaminophen

Given by mouth (PO).

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Dexamethasone

Given intravenously (IV).

OTHER

Electronic Health Record Review

Ancillary studies

DRUG

Famotidine

Given by mouth (PO).

DRUG

Loratadine

Given by mouth (PO).

DRUG

Methylprednisolone

Given intravenously (IV).

DRUG

Montelukast

Given by mouth (PO).

DRUG

Motixafortide

Given subcutaneously (SC).

PROCEDURE

Pheresis

Undergo apheresis

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Give Granulocyte Colony-Stimulating Factor (G-CSF).

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER